EDAP TMS SA annual report, Q4 FY2013

EDAP TMS S.A. — FY2013 Form 20-F

Business context and reporting period. This is the annual report for the fiscal year ended December 31, 2013, filed April 3, 2014; it does not provide standalone fourth-quarter results. EDAP develops and sells urology medical devices, principally extracorporeal shockwave lithotripsy (ESWL) systems and high-intensity focused ultrasound (HIFU) systems for prostate cancer. Financial statements are prepared under U.S. GAAP and reported in euros.

Financial performance and position

Metric (€ millions, except per-share data)20132012
Total revenue24.0826.07
Gross profit / gross margin9.32 / 38.7%10.43 / 40.1%
Operating loss(2.76)(2.03)
Net loss(5.02)(7.48)
Basic loss per share€(0.24)€(0.43)
Net cash used in operating activities(2.50)(0.16)
Cash and cash equivalents at year-end6.687.04
Cash plus short-term investments7.688.08

At year-end, total assets were €26.87 million, current assets €22.13 million, current liabilities €11.59 million, total liabilities €17.59 million and shareholders’ equity €9.28 million. Balance-sheet borrowings included €2.21 million of short-term borrowings, €0.33 million of long-term debt and €0.56 million of capital lease obligations. The prior $8.0 million non-convertible debentures were fully repaid in June 2013. Separately, the balance sheet carried €3.44 million of fair-value warrant liabilities.

HIFU sales were €5.1 million, down from €5.6 million; UDS sales were €19.0 million, down from €20.4 million. HIFU reported an operating loss of €0.7 million, while UDS generated €0.5 million of operating income.

Material changes versus 2012

  • Revenue fell 7.6%, mainly from lower lithotripsy equipment sales and the adverse Japanese yen/euro exchange-rate effect. UDS sold 45 devices versus 52 in 2012; HIFU sold two Ablatherm units and one Focal One versus four Ablatherm units.
  • Gross margin declined to 38.7% from 40.1%; operating loss widened as lower gross profit outweighed modestly lower operating expenses.
  • Net loss narrowed by €2.45 million, principally because net financial expense fell to €0.90 million from €4.59 million. The 2012 figure included a €2.25 million loss related to the January 2012 debt exchange.
  • Operating cash outflow increased to €2.50 million. Year-end cash and short-term investments declined by €0.40 million, despite the 2013 equity financing.

Outlook, commentary and risks

  • FDA and HIFU: EDAP submitted its Ablatherm premarket approval application in January 2013 and completed responses to FDA questions on March 19, 2014. An expert-panel meeting was expected within four to six months of the filing date. Approval, timing and the sufficiency of the clinical evidence remain uncertain; Ablatherm and Focal One were not approved for U.S. commercial distribution as of the report.
  • Funding and profitability: Management said working capital was sufficient for current needs, including the expected PMA process, but warned that significant FDA delays or new development projects could require additional capital or spending reductions. EDAP reported operating losses in every fiscal year since 1998 and stated that profitability was uncertain.
  • Management outlook: Beginning in 2014, management expected European R&D spending, excluding U.S. FDA trial costs, to be approximately 10% of revenue. Sales and marketing investment was expected to remain significant. Management described the ESWL market as mature, with intense price competition and demand largely driven by replacement equipment and service.
  • Commercial and operating risks: HIFU adoption depends partly on regulatory approval and reimbursement; reimbursement remained limited across markets. The company also cited seasonality, customer financing and collection risk, foreign-exchange exposure, competition, reliance on a single principal manufacturing site and single-source suppliers.
  • Warrants and dilution: Outstanding warrants and options could result in issuance of up to 4.259 million ADSs, approximately 19.2% of issued and outstanding share capital as of April 3, 2014, according to the filing. Warrant fair-value movements affected reported financial results.
  • Other items: A French administrative court rejected EDAP’s challenge concerning repayment of historical state aid; the filing describes €772,822 paid in connection with the matter. The company reported no material legal proceedings and no dividends paid or expected in the foreseeable future.

Investor verification priorities

  1. Check subsequent FDA panel activity, PMA review progress, any additional evidence requirements and the resulting cash cost and timetable.
  2. Assess liquidity against continuing operating cash outflows, debt and lease commitments, and potential need for additional financing.
  3. Review warrant and option terms, potential dilution, and the effect of warrant valuation changes on earnings and liabilities.
  4. Track sales volumes, margins and cash conversion in both divisions, including the contribution of recurring service, leasing and revenue-per-procedure activity.
  5. Evaluate HIFU reimbursement and adoption, foreign-exchange exposure, and exposure to key suppliers and the single manufacturing facility.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.